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ABSTRACT: Introduction: The site of pathology in myasthenia
gravis (MG) is the neuromuscular junction (NMJ). Our goal was
to determine the ability to direct complement inhibition to the
NMJ. Methods: A single-chain antibody directed against the
alpha subunit of the acetylcholine receptor was synthesized
(scFv-35) and coupled to decay-accelerating factor (DAF, scFv-
35-DAF). scFv-35-DAF was tested in a passive model of experi-
mentally acquired MG. Results: Administration of scFv-35-DAF
to mice deficient in intrinsic complement inhibitors produced no
weakness despite confirmation of its localization to the NMJ
and no evidence of tissue destruction related to complement
activation. Rats with experimentally acquired MG treated with
scFV-35-DAF showed less weakness and a reduction of com-
plement deposition. Conclusions: We demonstrate a method to
effectively target a therapeutic agent to the NMJ.
Muscle Nerve 49: 749–756, 2014
Myasthenia gravis (MG) is a prototypic antibody-
mediated autoimmune disease, which fulfills strict
criteria that define autoimmunity.1,2 MG is caused
primarily by antibodies directed against the skeletal
muscle nicotinic acetylcholine receptor (AChR),
which is concentrated on the postsynaptic surface
of the neuromuscular junction. The antibodies
produce a reduction in AChR number and damage
the muscle endplate. This leads to failure of neuro-
muscular transmission and produces weakness that
may be life-threatening. AChR antibodies of
patients with MG are polyclonal and recognize a
complex epitope repertoire that differs among
individuals. The heterogeneity of AChR antibodies
among patients is increased further by the variety
of light-chain and heavy-chain use. The antibody
synthesis is T-cell–dependent, and the epitope rep-
ertoire of AChR CD41 cells in MG patients is complex
and characteristic of the individual. Due to extreme
diversity of the immune response, specific suppression
of autoantibody production is an elusive goal.1,3
Therapies for MG fall into 2 broad categories4,5:
those that focus on enhancing neuromuscular
transmission by inhibition of cholinesterase, such as
pyridostigmine; or agents that suppress or modulate
the immune system, such as corticosteroids, azathio-
prine, tacrolimus, and mycophenolate mofetil.
Acute exacerbations of weakness are usually treated
with plasma exchange or intravenous immunoglo-
bulins, which act primarily through removal of
pathogenic antibody. All these treatments were
developed after initial use in other disorders6 and
produce systemic adverse effects. The immuno-
therapies are not aimed at production of the spe-
cific autoantibody in MG, but rather general
moderation of all immune responses, whether this
occurs through reduction of autoantibody levels
directly or indirectly through suppression of B- and
T-cell activity. The approach described here
attempts inhibition of a final effector mechanism of
pathogenic AChR antibody.
The AChR-specific antibodies induce disease by
3 mechanisms: (1) blocking binding and activation
of the AChR; (2) accelerating degradation of
AChR molecules cross-linked by antibodies
(“antigenic modulation”); and (3) mobilizing com-
plement at the NMJ.7–9 Autoantibodies are the
only effectors of myasthenic pathology, as patients
with MG do not have evidence of AChR-specific
cell-mediated mechanisms of NMJ injury.1,10
Therefore, treatments focused on inhibiting anti-
body effector mechanisms are likely to work rapidly
and be highly effective. Compromise of AChR func-
tion has not been found to be a major contributor
to limitation of neuromuscular transmission.1,2 Anti-
bodies from most MG patients accelerate the degra-
dation rate of the AChR in whole muscle tissue
culture and cultured muscle cells.11,12 However, not
all AChR antibodies are capable of antigenic modu-
lation, because the epitope location on the AChR
surface restricts antibody ability to cross-link a sec-
ond AChR molecule. Therefore, complement-
mediated injury is the primary mechanism for
pathology of the NMJ in MG.
Abbreviations: AChR, acetylcholine receptor; CCP, complement control
repeats; DAF, decay-accelerating factor; EAMG, experimentally acquired
myasthenia gravis; IC50, half-maximal inhibitory complex; MAC, mem-
brane attack complex; McAb, monoclonal antibody; MG, myasthenia
gravis; NMJ, neuromuscular junction; PCR, polymerase chain reaction;
scFv, single-chain antibody; SDS-PAGE, sodium dodecylsulfate–polyacryl-
amide gel electrophoresis
Key words: acetylcholine receptor; autoimmunity; complement; decay-
accelerating factor; myasthenia gravis
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The autoantibodies that bind to the AChR can
activate the complement cascade and produce lysis
of the NMJ through insertion of the membrane
attack complex (MAC). The NMJs of skeletal mus-
cle are protected from complement attack by spe-
cific cell-surface complement-regulatory proteins.13
Decay-accelerating factor (DAF or CD55), CD59,
and membrane cofactor protein (complement
receptor 1–related gene/protein y is the rodent
analog) reduce the activation of complement
through various pathways.14–18 The role of DAF as
a complement regulator is to accelerate the decay
of autologous C3 and C5 convertases. We assessed
the ability to target DAF to the NMJ and thereby
reduce the damage produced by complement acti-
vation. Concentrating DAF to the cell surface by a
fusion protein including an antibody binding
domain has been demonstrated to be effective in
inhibiting complement-mediated lysis.19
Eculizumab, the only complement inhibitor
available for human use, demonstrated signs of effi-
cacy in a small, pilot study of patients with severe
MG, and thus there is some support for comple-
ment inhibitor–based therapeutic approaches for
MG.20 However, to date, all inhibitor strategies have
led to systemic inhibition of complement. Here we
describe an approach that couples the complement-
inhibitory domains of the DAF molecule to a single-
chain antibody that binds the AChR. We used the
single-chain antibody as a control to assess whether
blocking pathogenic antibody binding could con-
tribute to a treatment effect. The expectation was
that concentration of complement inhibition to the
site of pathology could enhance efficacy without
compromising neuromuscular transmission.
METHODS
Animals. Daf12/2 mice21 were provided by M.E.
Medof (Case Western Reserve University) and
CD59ab2/2 mice were provided by J.A. Halperin
(Harvard Medical School, Boston, MA). Knockout
mouse strains were backcrossed 9 generations on
the C57Bc/6 background. CD59ab2/2Daf12/2
knockouts were prepared by cross-breeding
CD59ab2/2 and Daf12/2 mice. Genotyping to assure
knockout of the CD59 genes was performed as
described previously.22 To confirm that at least 1
copy of the Daf deletion construct was present, poly-
merase chain reaction (PCR) was performed with
specific primers (NeoFor: 50TGC TCC TGC CGA
GAA AGT AT 30 NeoRev: 50AAT ATC ACG GGT
AGC CAA CG 30); to assure that 2 copies of the dele-
tion construct were present, quantitative polymerase
chain reaction (PCR) was performed (NeoRT for-
ward: 50 AGACAATCGGCTGCTCTGAT 30 NeoRT
reverse: 50 TCGTCC TGCAGTTCATTCAG 30). Male
mice, 6–8 weeks old, were used for experiments to
determine localization of the scFv. Female Lewis rats
(Harlan, Indianapolis, Indiana), 6–10 weeks old,
were used for experimentally acquired MG (EAMG).
All animals were maintained in the Saint Louis Uni-
versity or George Washington University animal
facilities. Studies were carried out according to
approved protocols by the local institutional animal
care and use committees (IACUC).
Construction of Single-Chain Antibody Attached to
Decay-Accelerating Factor. We utilized the TIB-175
hybridoma cell line (ATCC), which produces
monoclonal antibody 35, an antibody known to
bind the AChR,23,24 for isolation of RNA and then
performed PCR amplification of variable heavy-
chain (VH) and variable light-chain (VL) regions.
We then performed overlapping PCR to generate
VH–VL fragment with a linker (GGGGS)3 to pro-
duce the single-chain AChR antibody scFv-35
(Fig. 1). Monoclonal antibody 35 (MAb-35) is an
antibody used commonly in EAMG studies.10,24,25
Constructs were produced with an IgG signal pep-
tide. To attach the DAF domains, we utilized the
C57Bl/6J for RNA and PCR to clone the 4 extrac-
ellular complement control protein modules of
255 amino acids and produced the scFv-35-Daf
(Fig. 2). We cloned all constructs into the pIRES2-
AcGFP1 vector (Clontech, Mountain View, Califor-
nia). This vector allows expression of 2 separate
proteins, 1 green fluorescent protein (GFP) and
the other protein of interest, rather than a single
fusion protein, which limits concerns regarding
the risk of loss of biological activity of the protein
of interest.
Transfection into BHK-21. BHK-21 cells, derived
from P1 hamster kidneys, were grown in 100-mm
dishes containing 10 ml of Eagle minimum essen-
tial medium supplemented with 10% fetal bovine
serum and antibiotics (growth medium). Transfec-
tion was performed with Lipofectin (Invitrogen,
FIGURE 1. Schematic of cloning strategy to produce scFv-35.
RNA from the TIB-175 hybridoma cell line was used to produce
the VH and VL regions of a monoclonal antibody that targets the
AChR.
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Carlsbad, California), following the manufacturer’s
protocol. Briefly, cells were plated at 1 3 105 on a
60-mm dish in growth medium, minus the antibiot-
ics, the day before transfection. The following day,
DNA was prepared by adding 2 lg of construct
(IgG-scFv-35 and IgG-scFv-35-DAF) to Opt-MEM
(Invitrogen) and combining it with the Lipofectin
solution. The resulting solution was added to cells
and incubated for 24 h at 37C. Stable transfected
cell lines were selected using G418 (200 lg/ml) in
growth medium. Positive cells were detected by
expression of GFP. Clones were selected and
expanded in growth medium supplemented with
G418. Cells were placed in serum-free and protein-
free growth medium for collection of secreted
recombinant protein. Collected medium was puri-
fied by Antibody Research (St. Charles, Missouri),
and the resulting recombinant protein was ana-
lyzed with 12% sodium dodecylsulfate sulfate–poly-
acrylamide gel electrophoresis (SDS-PAGE),
followed by detection with Coomassie Blue G-250
(Bio-Rad, Hercules, California).
Complement Hemolytic Assay. Complement inhibi-
tion by scFv-35-DAF was assessed by hemolytic assay
using sensitized sheep erythrocytes (Complement
Technologies, Tyler, Texas) and rat serum, as a
source of complement. Rat serum was diluted
1:200 and added to a concentration of scFv-35 or
scFv-35-DAF ranging from 0.1 to 100 nM. Comple-
ment activity was initiated by addition of 100 ll of
2 3 108 sensitized sheep erythrocytes in Veronal
buffer and incubated at 37C for 1 h. After 60
min, sheep cells were removed by centrifugation,
and complement hemolysis was measured at
412 nm (SpectraMax 340; Molecular Devices,
Sunnyvale, California). Data are shown as a per-
centage of inhibition based on 100% lysis values.
Evaluation of scFv-35 and scFv-35–DAF into C57Bl/6
and CD59ab2/2Daf12/2 Mice. We utilized 2 groups
of 4 mice on both C57Bl/6 and CD59ab2/2Daf12/2
strains. Mice were injected with 234 lg of scFv-35 or
scFv-35-DAF and monitored for 24 h for weakness or
signs of stress. Grip strengths were determined by
ability to lift cage lids consecutive times. A generally
accepted motor strength scale was used to assess for
weakness: 0 5 can grip and lift lid of the cage;
1 5 can grip but cannot lift the lid of the cage;
2 5 unable to grip cage lid; 3 5 unable to grip plus
hindlimb paralysis; and 4 5 moribund.26 After 24 h,
the mice were euthanized, and diaphragms were
removed for analysis.
Induction of EAMG in Lewis Rats. To determine the
efficacy of the scFv-35-DAF recombinant protein,
15 rats were grouped randomly and given scFv-35,
scFv-35-DAF, or vehicle by intraperitoneal injec-
tion. One hour later, EAMG was induced by
administration of rat anti-mouse muscle AChR
MAb McAb-3 (gift of Vanda Lennon, Mayo
Clinic27), similar to our previous investigations [50
ll of purified McAb-3 (4.6 mg/ml)].21,28,29 McAb-3
is an IgG2b isotype known to activate complement.
Rats were kept under close observation and eval-
uated daily. A generally accepted motor strength
scale was used to assess for weakness.26 Animals
underwent euthanasia after 48 h, and diaphragms
were removed for analysis.
Immunohistochemistry and Fluorescence Quantitation.
For analysis of localization of scFv-35 to the neuro-
muscular junction, the diaphragms of mice were
analyzed. Cryosections of diaphragm at 10 lm
were stained with Alexa 488–labeled anti-rat IgG
(Molecular Probes) and Alexa 594–labeled bungar-
otoxin (BTX) for identification of NMJs. For
FIGURE 2. The 529-amino-acid sequence of the scFv-35-DAF
construct. Each of the functional domains and corresponding
sequences are indicated: IgGsp (signal peptide); VH (variable
heavy chain); linker; VL (variable light chain); and DAF (decay-
accelerating factor).
FIGURE 3. Expression and complement inhibition activity of
scFv-35-DAF. (A) SDS-PAGE gel: lane 1—protein standards;
lane 2—rat IgG; lane 3—scFv-35-DAF. (B) The scFv-35-DAF
recombinant protein inhibits minimal cell lysis at a 5-nM con-
centration, a maximal 76.61 6 3.89% inhibitory capacity at
100 nM, and an estimated CH50 of 9 nM. The scFV-35 demon-
strates no native complement inhibitory potential.
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analysis of EAMG-induced rats treated with scFv-35
and scFv-35-DAF or PBS controls, diaphragm tis-
sues were cryosectioned at 10 lm and stained for
membrane attack complex (MAC) deposition.
Briefly, rabbit polyclonal anti-complement 5b-9
(Calbiochem) diluted 1:100 was incubated on sec-
tions for 1 h. Alexa 488–labeled anti-rabbit IgG
(Molecular Probes) was used to detect MAC and
Alexa 594–labeled BTX was used to identify NMJs.
The sections were viewed with a fluorescence
microscope (BX50; Olympus, Center Valley, Penn-
sylvania), and digital images were captured with a
Spot camera (Diagnostic Instruments, Sterling
Heights, Michigan) and analyzed with ImagePro
software (Media Cybernetics, Silver Springs, Mary-
land). Adobe Photoshop and Illustrator (Adobe
Systems, Inc., Seattle, Washington) software
programs were used to prepare the figures. All
BTX-stained junctions in 9–12 randomly selected
fields were counted, and MAC immunoreactivity of
these junctions was determined. Pixel density
measurements were used to quantitate fluores-
cence at the neuromuscular junctions. A total of
80 NMJs were analyzed in each group. The percent
of endplates with specific pixel density was
expressed in a histogram.
Statistical Analysis. The data were analyzed and
tested for statistical significance using paired
Mann–Whitney U-tests. P< 0.05 was considered
significant.
RESULTS
scFv-35 and scFv-35-DAF. The sequence of the
combined scFv-35-DAF is shown in Figure 2 and
confirms the identity of the construct.
FIGURE 4. C57Bl/6 and CD59ab2/2Daf12/2 mice were injected with scFv-35 and killed 24 h later. Animals did not demonstrate weak-
ness. (A) Diaphragm cryosections from scFv-35–injected c57Bl/6 and CD59ab2/2Daf12/2 mice were stained with Alexa 488–conju-
gated anti-rat IgG (green). Alexa 594–conjugated a-BTX (red) identifies the NMJs. (B) CD59ab2/2Daf12/2 mice demonstrated no
evidence of MAC deposition. Diaphragms from scFv-35–injected CD59ab2/2Daf12/2 mice were stained with anti-MAC and detected
with Alexa 488–conjugated anti-rabbit IgG. Alexa 594–conjugated a-BTX identifies the NMJs.
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Recombinant protein was collected in serum-free
and protein-free medium. SDS-PAGE gel was run
to confirm size and purity of scFv-35-DAF
(Fig. 3A). The recombinant protein is 529 amino
acids with an expected size of 57.7 kDa.
Complement Inhibition of scFv-35-DAF. We per-
formed a serial dilution to assess the ability of
scFv-35-DAF to inhibit lysis of sensitized sheep red
blood cells. The scFv-35 alone had no demonstrable
effect on inhibition of cell lysis. The scFv-35-DAF
inhibited cell lysis by 76.61 6 3.89% at a concentration
of 100 nM (Fig. 3B) and an estimated CH50 of 9 nM.
Evaluation of Toxicity of scFv-35-DAF. Administration
of an antibody directed toward the AChR carries
the risk of blocking neuromuscular transmission
and potentially activating complement. We utilized
C57Bl/6 mice and mice deficient in both CD59ab
and Daf1, which have demonstrated severe,
complement-mediated weakness within 24 h of
EAMG induction.28,30,31 Injection of scFv-35 into
C57Bl/6 and CD59ab2/2Daf12/2 mice showed no
observable pathology. The mice maintained
strength and mobility over the 24-h period.
We were able to demonstrate that, at 24 h, scFv-
35 ?A3B2 thyc?> localized to the NMJ in the
C57Bl/6 and CD59ab2/2Daf12/2 mice (Fig. 4).
Furthermore, the NMJs of CD59ab2/2Daf12/2
animals showed no evidence of MAC formation
(Fig. 4).
Therapeutic Effect of scFv-35 and scFv-35-DAF.
After 24 h of EAMG induction, PBS-treated and
scFv-35–treated rats began to show weakness, which
was not evident in the scFv-35-DAF–treated rats
(Fig. 5). By 48 h, vehicle- and scFv-35–treated rats
had become profoundly weak (clinical scores of
3.4 6 0.55 and 3.4 6 0.89, respectively) to the point
of requiring euthanasia, whereas scFv-35-DAF–
treated rats had developed only moderate weak-
ness (clinical score of 2 6 0, P< 0.01 compared
with both scFv-35 and PBS; Fig. 5). All animals
were then killed for histological analysis. Quantita-
tive analysis of complement deposition demon-
strated significantly less MAC deposition at
endplates of scFv-35-DAF–treated animals (mean
1226 6 610 pixel density) compared with both vehi-
cle- and scFv-35–treated rats (mean 1611 6 644
pixel density and 1979 6 453 pixel density, respec-
tively; P< 0.01 compared with scFv-DAF treated),
whereas scFv-35–treated rats had a marginally
higher degree of complement deposition com-
pared with vehicle-treated rats (Fig. 6). Consistent
with the better clinical outcome, AChR density was
significantly greater in the scFv-35-DAF–treated rats
(mean 3208 6 953 pixel density) than scFv-35–
treated and vehicle-treated rats (means 1489 6 865
pixel density and 1128 6 716 pixel density, respec-
tively; P< 0.001 compared with scFv-35-DAF).
DISCUSSION
In this study we have demonstrated the feasibil-
ity of concentrating a therapeutic agent at the
NMJ without producing neuromuscular blockade
or activation of complement. The scFv-35 was pro-
duced from the well-characterized McAb-35, which
is known to bind the main immunogenic region
on the extracellular surface of the rat a-subunit of
the AChR. We confirmed that the scFv-35 localized
to the NMJ and is stable for 24 h. Despite scFv-35
binding to the junction, c57Bl/6 and complement-
deficient mice demonstrated no weakness. This
indicates that the AChR can be used as a target to
concentrate therapeutics to the NMJ (Fig. 7). We
showed that the scFv-35-DAF constructed inhibited
complement-mediated lysis of sheep red blood
cells in vitro, whereas the scFv-35 itself had no such
inhibitory activity. Despite using CD59ab2/2Daf12/2
mice, which are highly susceptible to complement
activation by antibody,28,30,31 there was no immu-
nohistochemical evidence of complement activa-
tion. The scFv-35 was engineered to lack the Fc
portion, and we did not expect it to activate com-
plement. In both mice deficient in intrinsic com-
plement inhibitors (data not shown) and Lewis
rats, we found the scFv-35-DAF moderated passive
EAMG severity with reduced weakness, lessened
MAC deposition, and preserved AChR density. Our
FIGURE 5. Clinical scores of EAMG-induced rats treated with
scFv-35 (shaded bars), scFv-35-DAF (black bars), and PBS
(white bars). (A) Rats were treated with scFv-35-DAF, scFv-35,
or PBS control before being induced with MAb 3. The rats
treated with scFv-35-DAF had no weakness at 24 h and mini-
mal weakness at 48 h with vehicle-treated and scFv-35–treated
rats (#P<0.05 vs. scFv-35-DAF, *P<0.01 vs. scFv-35-DAF).
(B) Table of clinical scores for scFv-35, scFv-35-DAF, and PBS
treatment at 24 h and 48 h.
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findings are most likely explained by the
complement-inhibitory effect of the scFv-35-DAF.
We found the half-maximal inhibitory concentra-
tion (IC50) for scFv-35-DAF to be 9 nM, whereas
scFv-35 alone did not inhibit complement. The
IC50 compares favorably with that of eculizumab,
the only complement inhibitor in clinical use,
which is estimated to be in the range of 1–290
nM.32,33
We did not completely ablate the effects of
EAMG, but only a single dose was evaluated. Opti-
mization of dosing would be expected to improve
efficacy, and, as with other therapeutics for human
MG, repeat dosing would be required. Another
limitation of our study is that we chose to treat ani-
mals with the scFv-35-DAF prior to EAMG induc-
tion to optimize the potential to detect a
treatment effect. Further studies are required to
assure that scFv-35-DAF can reduce EAMG severity
after induction of disease.
Antigenic modulation, which occurs through
cross-linking of AChR by the bivalent antibody and
thereby increases internalization of receptor, con-
tributes to reductions of AChR density and
consequent development of weakness.1–4 Based on
previous studies, monovalent AChR antibodies
have not been demonstrated to induce disease and
therefore there was an expectation that the scFv-35
would not induce weakness. As expected, the scFv-
35 did not produce weakness in the CD59ab2/2
Daf12/2 mice, but one may have expected in
EAMG experiments that the scFv-35 would reduce
severity of EAMG-induced weakness. Fab fragments
produced from McAb-35 moderate the severity of
FIGURE 6. Membrane attack complex and AChR assessment after 48 h of induction of EAMG. (A) Diaphragms from EAMG-induced
rats were cryosectioned and stained for MAC. Alexa 488–conjugated anti-rabbit IgG was used to detect MAC antibody. Alexa 594–con-
jugated a-BTX identified NMJs. (B) Fluorescent images were assessed for pixel density of MAC deposition at the NMJ. A distribution
plot was constructed based on percent of endplates that expressed a specific pixel range (P<0.01 for scFv-35-DAF vs. scFv-35 and
control). (C) Alexa 594–conjugated a-BTX bound to AChR at the NMJs were assessed by pixel density. A distribution plot was con-
structed with percent NMJs identified within a range of pixel density.
FIGURE 7. Schematic of mode of action of scFv-35-DAF. The
figure illustrates the hypothesis of AChR being targeted by a
single-chain antibody and concentrating DAF to the NMJ. Size
differences among molecules are approximate.
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EAMG induced by the whole antibody.35 We have
limited evidence that any blockade of pathogenic
antibody occurred in this experiment. The scFv-35
produced no moderation of disease severity and
did not reduce complement activation, which
could have been expected if the scFv-35 reduced
pathogenic antibody binding with subsequent com-
plement activation. The addition of the DAF
domains to the scFv-35 could conceivably produce
a blocking effect, but given the demonstration of
reduced MAC deposition, it is most reasonable to
consider the complement-inhibitory effect to be
primary. Surprisingly, administration of scFv-35 to
rats with EAMG produced a moderate increase in
complement deposition and a reduced AChR den-
sity compared with EAMG rats given PBS alone.
We are unaware of any antibody directed to the
AChR that leads to activation of the ion channel,10
and there is none for the McAb-35 itself. There-
fore, we do not believe svFc-35-DAF could have an
agonist effect.
Blockade of AChR function could contribute to
weakness,36 which led to significant concern that
the scFv-35 could produce weakness. There was no
evidence that the scFv-35 blocked channel func-
tion; however, we did not perform electrophysio-
logical studies to assess subclinical compromise of
neuromuscular transmission. Both mice and
humans share the property of a high safety factor
for neuromuscular transmission,37 and therefore
small effects of scFv-35 and scFv-35-DAF on trans-
mission would not have been identified by behav-
ioral evaluations. However, even in animals with
EAMG, scFv-35 and scFv-35-DAF did not worsen
disease.
Although intravenous immunoglobulin treat-
ment may moderate the severity of human MG
and EAMG,38 it is unlikely that our findings can be
explained only by infusion of immunoglobulin.
First, scFv-35 had no effect on EAMG severity. Sec-
ond, intravenous immunoglobulin appears to mod-
erate EAMG by anti-idiotype mechanisms, which is
unlikely to have occurred in our experimental par-
adigm.38,39 Finally, a study of intravenous immuno-
globulin utilized a dose of 0.4 g/kg per rat, which
is about 200 times the dose of scFv-35-DAF used in
our study.40
As a complement inhibitor, we utilized the regu-
latory region of DAF, which is composed of 60-
amino-acid-long repeating domains and acts effi-
ciently on both the classical and alternative path-
ways.41,42 In DAF, 4 of these complement control
repeats (CCPs) are suspended above the surface
membrane. In a series of experiments, we and
others have demonstrated that mice deficient in Daf
and another cell surface complement inhibitor,
CD59, are extremely susceptible to EAMG,28–31
which suggests that the DAF-inhibitory domain
could function effectively in disease moderation, as
demonstrated in this report. One investigation43
described construction of a single-chain antibody
directed at the AChR coupled to DAF, which also
was found to concentrate to the NMJ; however, the
investigators did not evaluate for therapeutic effi-
cacy in animals. Linking CCP domains of DAF to a
viral vector has been successful in delivering DAF to
the cell surface, leading to protection from
complement-mediated injury.44 Delivery of DAF to
the cell surface of erythrocytes protects them from
complement-mediated lysis.45 Coupled with the
present investigation, these studies support the use
of DAF-based constructs as therapeutic complement
inhibitors.
Complement inhibitors are in their develop-
mental infancy,46 but they are a subject of intense
interest.47 Presently, only 1 first-generation inhibi-
tor, eculizumab, is FDA approved for paroxysmal
nocturnal hemoglobinuria and atypical hemolytic
uremic syndrome. Eculizumab also carries the dis-
tinction of being the most expensive medication
on the market.48 Development of more advanced
complement-based therapeutics will likely to be
refined to focus inhibition on specific steps of the
activation cascade tailored to specific pathology as
well as enhancing potency. Here we have demon-
strated the feasibility of concentrating complement
inhibition to a site of pathology, which is an addi-
tional refinement needed for complement therapy
development.
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